IGF1R [52], RIPK1 [53], and PSEN2 [54] are already known to contribute to vemurafenib resistance, suggesting that our new analysis method using v reliably identified hits whose ablation can sensitize melanoma to vemurafenib. This evidence concerns the gene PSEN2 and melanoma.